You are not currently logged in.
Access JSTOR through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Mutations in FN1 Cause Glomerulopathy with Fibronectin Deposits
Federica Castelletti, Roberta Donadelli, Federica Banterla, Friedhelm Hildebrandt, Peter F. Zipfel, Elena Bresin, Edgar Otto, Christine Skerka, Alessandra Renieri, Marta Todeschini, Jessica Caprioli, Maria Rosa Caruso, Rosangela Artuso, Giuseppe Remuzzi and Marina Noris
Proceedings of the National Academy of Sciences of the United States of America
Vol. 105, No. 7 (Feb. 19, 2008), pp. 2538-2543
Published by: National Academy of Sciences
Stable URL: http://www.jstor.org/stable/25451502
Page Count: 6
You can always find the topics here!Topics: Proteinuria, Genetic mutation, Biopsies, Diabetic nephropathies, Heparin, Endothelial cells, Kidney cortex, Antibodies, Haplotypes, Human umbilical vein endothelial cells
Were these topics helpful?See something inaccurate? Let us know!
Select the topics that are inaccurate.
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Glomerulopathy with fibronectin (FN) deposits (GFND) is an autosomal dominant disease with age-related penetrance, characterized by proteinuria, microscopic hematuria, hypertension, and massive glomerular deposits of FN that lead to end-stage renal failure. The genetic abnormality underlying GFND was still unknown. We hypothesized that mutations in FN1, which encodes FN, were the cause of GFND. In a large Italian pedigree with eight affected subjects, we found linkage with GFND at the FN1 locus at 2q32. We sequenced the FN1 in 15 unrelated pedigrees and found three heterozygous missense mutations, the W1925R, L1974R, and Y973C, that cosegregated with the disease in six pedigrees. The mutations affected two domains of FN (Hep-II domain for the W1925R and the L1974R, and Hep-III domain for the Y973C) that play key roles in FN-cell interaction and in FN fibrillogenesis. Mutant recombinant Hep-II fragments were expressed, and functional studies revealed a lower binding to heparin and to endothelial cells and podocytes compared with wild-type Hep-II and an impaired capability to induce endothelial cell spreading and cytoskeletal reorganization. Overall dominant mutations in FN1 accounted for 40% of cases of GFND in our study group. These findings may help understanding the pathogenesis of proteinuria and glomerular FN deposits in GFND and possibly in more common renal diseases such as diabetic nephropathy, IgA nephropathy, and lupus nephritis. To our knowledge no FN1 mutation causing a human disease was previously reported.
Proceedings of the National Academy of Sciences of the United States of America © 2008 National Academy of Sciences